Evidence map›Paper›PMID 39979825›Full record

ArticleBMC cancer2025

The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma.

Matthias Schneider, Anna-Laura Potthoff, Yahya Ahmadipour, Valeri Borger, Hans Clusmann, Stephanie E Combs, Marcus Czabanka, Lasse Dührsen, Nima Etminan, Thomas M Freiman and 66 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07021339 (Randomized, Controlled Trial of Anterior Temporal Lobectomy Versus Gross Total Resection in Newly-diagnosed Temporal Glioblastoma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07021339 phase3recruitingnot on this map

Randomized, Controlled Trial of Anterior Temporal Lobectomy Versus Gross Total Resection in Newly-diagnosed Temporal Glioblastoma (ATLAS/NOA-29)

TypeinterventionalSponsorUniversity Hospital, BonnRan2024 to 2031Enrolled178ConditionsNewly-diagnosed Glioblastoma, Temporal LobeArmsAnterior temporal lobectomy (ATL), Gross Total Resection (GTR)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

76 authors.

Matthias SchneiderDepartment of Neurosurgery, University Hospital Bonn, Venusberg Campus 1, Bonn, 53127, Germany. matthias.schneider@ukbonn.de.
Anna-Laura PotthoffDepartment of Neurosurgery, University Hospital Bonn, Venusberg Campus 1, Bonn, 53127, Germany.
Yahya AhmadipourDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany.
Valeri BorgerDepartment of Neurosurgery, University Hospital Bonn, Venusberg Campus 1, Bonn, 53127, Germany.
Hans ClusmannDepartment of Neurosurgery, RWTH Aachen University Hospital, Aachen, Germany.
Stephanie E CombsDepartment of Radiation Oncology, Klinikum Rechts Der Isar, Technical University of Munich (TUM), Munich, Germany.
Marcus CzabankaDepartment of Neurosurgery, University Hospital Frankfurt, Frankfurt, Germany.
Lasse DührsenDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Nima EtminanDepartment of Neurosurgery, University Hospital Mannheim, Mannheim, Germany.
Thomas M FreimanDepartment of Neurosurgery, University Medical Center Rostock, Rostock, Germany.
Ruediger GerlachDepartment of Neurosurgery, Helios Kliniken, Erfurt, Germany.
Florian GesslerDepartment of Neurosurgery, University Medical Center Rostock, Rostock, Germany.
Frank A GiordanoDepartment of Radiation Oncology, University Hospital Mannheim, Mannheim, Germany.
Eleni GkikaDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Roland GoldbrunnerDepartment of General Neurosurgery, Center of Neurosurgery, University of Cologne, Cologne, Germany.
Erdem GüresirDepartment of Neurosurgery, University Hospital Leipzig, Leipzig, Germany.
Hussam HamouDepartment of Neurosurgery, RWTH Aachen University Hospital, Aachen, Germany.
Peter HauDepartment of Neurology and Wilhelm Sander-Therapy Unit, Regensburg University Medical Center, Regensburg, Germany.
Sebastian IlleDepartment of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.
Max JägersbergDepartment of Neurosurgery, University Medical Center Mainz, Mainz, Germany.
Naureen KericDepartment of Neurosurgery, University Medical Center Schleswig-Holstein/Lübeck, Lübeck, Germany.
Maryam Khaleghi-GhadiriDepartment of Neurosurgery, University Hospital of Münster, Münster, Germany.
Ralph KönigDepartment of Neurosurgery, University of Ulm, Günzburg, Germany.
Jürgen KonczallaDepartment of Neurosurgery, University Hospital Frankfurt, Frankfurt, Germany.
Harald KrenzlinDepartment of Neurosurgery, University Medical Center Schleswig-Holstein/Lübeck, Lübeck, Germany.
Sandro KriegDepartment of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany.
Aaron Lawson McLeanDepartment of Neurosurgery, Jena University Hospital, Jena, Germany.
Julian P LayerDepartment of Radiation Oncology, University Hospital Bonn, Bonn, Germany.
Jens LehmbergDepartment of Neurosurgery, München Klinik Bogenhausen, Munich, Germany.
Vesna MalinovaDepartment of Neurosurgery, University Medical Center Göttingen, Göttingen, Germany.
Bernhard MeyerDepartment of Neurosurgery, Klinikum Rechts Der Isar, Technical University of Munich (TUM), Munich, Germany.
Hanno S MeyerDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Dorothea MillerDepartment of Neurosurgery, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
Oliver MüllerNeurosurgical Department, Dortmund Hospital, Dortmund, Germany.
Christian MusahlDepartment of Neurosurgery, Kantonspital Aarau, Aarau, Switzerland.
Barbara E F PreglerDepartment of Neurosurgery, University Hospital Bonn, Venusberg Campus 1, Bonn, 53127, Germany.
Ali RashidiDepartment of Neurosurgery, University Hospital Magdeburg, Magdeburg, Germany.
Florian RingelDepartment of Neurosurgery, Ludwig Maximilian University (LMU) Hospital, Munich, Germany.
Constantin RoderDepartment of Neurosurgery, University Hospital Tübingen, Tübingen, Germany.
Karl RösslerDepartment of Neurosurgery, Medical University of Vienna, Vienna, Austria.
Veit RohdeDepartment of Neurosurgery, University Medical Center Göttingen, Göttingen, Germany.
I Erol SandalciogluDepartment of Neurosurgery, University Hospital Magdeburg, Magdeburg, Germany.
Niklas SchäferDepartment of Neurooncology, Center of Neurology, University Hospital Bonn, Bonn, Germany.
Christina SchaubDepartment of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
Nils Ole SchmidtDepartment of Neurosurgery, University Hospital Regensburg, Regensburg, Germany.
Gerrit A SchubertDepartment of Neurosurgery, RWTH Aachen University Hospital, Aachen, Germany.
Clemens SeidelDepartment of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany.
Corinna SeligerDepartment of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
Christian SenftDepartment of Neurosurgery, Jena University Hospital, Jena, Germany.
Julia ShawarbaDepartment of Neurosurgery, Medical University of Vienna, Vienna, Austria.
Joachim SteinbachDr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Frankfurt, Germany.
Veit StöckleinDepartment of Neurosurgery, Ludwig Maximilian University (LMU) Hospital, Munich, Germany.
Walter StummerDepartment of Neurosurgery, University Hospital of Münster, Münster, Germany.
Ulrich SureDepartment of Neurosurgery and Spine Surgery, University Hospital Essen, Essen, Germany.
Ghazaleh TabatabaiDepartment of Neurology and Interdisciplinary Neuro-Oncology, Hertie Institute for Clinical Brain Research, University Hospital Tübingen, Tübingen, Germany.
Marcos TatagibaDepartment of Neurosurgery, University Hospital Tübingen, Tübingen, Germany.
Niklas ThonDepartment of Neurosurgery, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.
Marco TimmerDepartment of General Neurosurgery, Center of Neurosurgery, University of Cologne, Cologne, Germany.
Johannes WachDepartment of Neurosurgery, University Hospital Leipzig, Leipzig, Germany.
Arthur WagnerDepartment of Neurosurgery, Klinikum Rechts Der Isar, Technical University of Munich (TUM), Munich, Germany.
Christian Rainer WirtzDepartment of Neurosurgery, University of Ulm, Günzburg, Germany.
Katharina ZeilerDepartment of Neurosurgery, München Klinik Bogenhausen, Munich, Germany.
Thomas ZeyenBrain Tumor Translational Research Group, University Hospital Bonn, Bonn, Germany.
Patrick SchussDepartment of Neurosurgery, Unfallkrankenhaus Berlin, Berlin, Germany.
Rainer SurgesDepartment of Epileptology, University Hospital Bonn, Bonn, Germany.
Christine FuhrmannClinical Study Core Unit Bonn, Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
Daniel PaechDepartment of Neuroradiology, University Hospital Bonn, Bonn, Germany.
Matthias SchmidInstitute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
Yvonne BorckClinical Study Core Unit Bonn, Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
Torsten PietschDepartment of Neuropathology, University Hospital Bonn, Bonn, Germany.
Rafael StruckClinical Study Core Unit Bonn, Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
Alexander RadbruchInstitute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
Christoph HelmstaedterDepartment of Epileptology, University Hospital Bonn, Bonn, Germany.
Robert NémethInstitute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Bonn, Germany.
Ulrich Herrlinger *Brain Tumor Translational Research Group, University Hospital Bonn, Bonn, Germany.
Hartmut Vatter *Department of Neurosurgery, University Hospital Bonn, Venusberg Campus 1, Bonn, 53127, Germany.

Funding

Deutsche Krebshilfe 70114652
6 · The paper itself

Abstract

backgroundThe discovery of cellular tumor networks in glioblastoma, with routes of malignant communication extending far beyond the detectable tumor margins, has highlighted the potential of supramarginal resection strategies. Retrospective data suggest that these approaches may improve long-term disease control. However, their application is limited by the proximity of critical brain regions and vasculature, posing challenges for validation in randomized trials. Anterior temporal lobectomy (ATL) is a standardized surgical procedure commonly performed in patients with pharmacoresistant temporal lobe epilepsy. Translating the ATL approach from epilepsy surgery to the neuro-oncological field may provide a model for investigating supramarginal resection in glioblastomas located in the anterior temporal lobe.

methodsThe ATLAS/NOA-29 trial is a prospective, multicenter, multinational, phase III randomized controlled trial designed to compare ATL with standard gross-total resection (GTR) in patients with newly-diagnosed anterior temporal lobe glioblastoma. The primary endpoint is overall survival (OS), with superiority defined by significant improvements in OS and non-inferiority in the co-primary endpoint, quality of life (QoL; "global health" domain of the European organization for research and treatment of cancer (EORTC) QLQ-C30 questionnaire). Secondary endpoints include progression-free survival (PFS), seizure outcomes, neurocognitive performance, and the longitudinal assessment of six selected domains from the EORTC QLQ-C30 and BN20 questionnaires. Randomization will be performed intraoperatively upon receipt of the fresh frozen section result. A total of 178 patients will be randomized in a 1:1 ratio over a 3-year recruitment period and followed-up for a minimum of 3 years. The trial will be supervised by a Data Safety Monitoring Board, with an interim safety analysis planned after the recruitment of the 57th patient to assess potential differences in modified Rankin Scale (mRS) scores between the treatment arms 6 months after resection. Assuming a median improvement in OS from 17 to 27.5 months, the trial is powered at > 80% to detect OS differences with a two-sided log-rank test at a 5% significance level. DISCUSSION: The ATLAS/NOA-29 trial aims to determine whether ATL provides superior outcomes at equal patients' Qol compared to GTR in anterior temporal lobe glioblastoma, potentially establishing ATL as the surgical approach of choice for isolated temporal glioblastoma and redefining the standard of care for this patient population.

trial registrationGerman Clinical Trials Register (DRKS00035314), registered on October 18, 2024.

Indexed as

Anterior Temporal LobectomyBrain NeoplasmsGlioblastomaTemporal LobeAdultClinical Trials, Phase III as TopicEquivalence Trials as TopicFemaleHumansMaleMulticenter Studies as TopicProspective StudiesQuality of LifeRandomized Controlled Trials as TopicTreatment OutcomeAnterior temporal lobectomyEpilepsy surgeryGross-total resectionSupramarginal resectionTemporal lobe glioblastoma

Identifiers

PMID39979825
PMCPMC11843818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.